Belvisi A, Matergi M, Fici F
Int J Clin Pharmacol Ther Toxicol. 1982 Mar;20(3):142-6.
After pyridoxine-alpha-ketoglutarate (PAK) was administered to patients with hepatic cirrhosis, the blood level values for lactic acid and ammonia showed a statistically significant reduction. These results suggest that PAK can be used for treatment adn prevention of hyperlactacidemia secondary to chronic hepatopathy.
在给肝硬化患者施用吡哆醇-α-酮戊二酸（PAK）后，乳酸和氨的血液水平值显示出统计学上的显著降低。这些结果表明，PAK可用于治疗和预防继发于慢性肝病的高乳酸血症。
